Evading apoptosis in cancer

Trends in Cell Biology

Volumn 23, Issue 12, 2013, Pages 620-633

  Fernald, Kaleigh ^a   Kurokawa, Manabu ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

BH3; Caspase; MOMP; Phosphorylation; Ubiquitination

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 199; ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ATB 199; ATB 263; BIM PROTEIN; CASPASE 2; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CYCLIN B; CYCLIN DEPENDENT KINASE 1; GLYCOGEN SYNTHASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NAVITOCLAX; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ASTROCYTOMA; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ESOPHAGEAL ADENOCARCINOMA; FOLLICULAR LYMPHOMA; GENE AMPLIFICATION; GENE LOSS; GLIOBLASTOMA; HUMAN; INTRACELLULAR SIGNALING; KIDNEY CANCER; LIPOSARCOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; MELANOMA; NONHUMAN; OSTEOCLASTOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; RNA TRANSLATION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TRANSCRIPTION REGULATION; UBIQUITINATION; UTERINE CERVIX CANCER;

BH3; CASPASE; MOMP; PHOSPHORYLATION; UBIQUITINATION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS;

EID: 84888197229     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2013.07.006     Document Type: Review

References (199)

1. Martinou J.C., Youle R.J. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev. Cell 2011, 21:92-101.
2. Strasser A., et al. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011, 30:3667-3683.
3. Rautureau G.J., et al. The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist. Cell Death Dis. 2012, 13:e443.
4. Hübner A., et al. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol. Cell 2008, 30:415-425.
5. Bean G.R., et al. PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci. Signal. 2013, 6:ra20.
6. Parsons M.J., et al. Genetic deletion of caspase-2 accelerates MMTV/c-neu-driven mammary carcinogenesis in mice. Cell Death Differ. 2013, 10.1038/cdd.2013.38.
7. Strasser A., et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990, 348:331-333.
8. Brunelle J.K., et al. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J. Cell Biol. 2009, 187:429-442.
9. Vaux D.L., et al. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1998, 335:440-442.
10. Zhou P., et al. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 1998, 92:3226-3239.
11. Vander-Heiden M.G., et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
12. Buchakjian M.R., Kornbluth S. The engine driving the ship: metabolic steering of cell proliferation and death. Nat. Rev. Mol. Cell Biol. 2010, 11:715-727.
13. Kumar S., Cakouros D. Transcriptional control of the core cell-death machinery. Trends Biochem. Sci. 2004, 29:193-199.
14. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
15. Kaufmann S.H., et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998, 91:991-1000.
16. Taniai M., et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 2004, 64:3517-3524.
17. Wuilleme-Toumi S., et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005, 19:1248-1252.
18. Bakhshi A., et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985, 41:899-906.
19. Cleary M.L., Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:7439-7443.
20. Tsujimoto Y., et al. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985, 229:1390-1393.
21. Tonon G., et al. High-resolution genomic profiles of human lung cancer. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:9625-9630.
22. Smith L.T., et al. 20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome. Genes Chromosomes Cancer 2006, 45:957-966.
23. Beroukhim R., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
24. Kendall J., et al. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16663-16668.
25. Wang J.M., et al. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell. Biol. 1999, 9:6195-6206.
26. Huang H.M., et al. Mcl-1 is a common target of stem cell factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/Akt pathways. Blood 2000, 96:1764-1771.
27. Liu H., et al. Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 2003, 102:344-352.
28. Nijhawan D., et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 2003, 17:1475-1486.
29. Fritsch R.M., et al. Translational repression of MCL-1 couples stress-induced eIF2 alpha phosphorylation to mitochondrial apoptosis initiation. J. Biol. Chem. 2007, 282:22551-22562.
30. Croxton R., et al. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 2002, 21:1359-1369.
31. Mills J.R., et al. mTORC1 promotes survival through translational control of Mcl-1. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10853-10858.
32. Cimmino A., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:13944-13949.
33. Mott J.L., et al. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007, 26:6133-6140.
34. Kwon J.E., et al. Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1. Apoptosis 2013, 18:896-909.
35. Su H., et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009, 69:1135-1142.
36. Kole A.J., et al. miR-29b is activated during neuronal maturation and targets BH3-only genes to restrict apoptosis. Genes Dev. 2011, 25:125-130.
37. Xie Y., et al. MicroRNA-24 regulates XIAP to reduce the apoptosis threshold in cancer cells. Oncogene 2012, 32:2442-2451.
38. Liu S., et al. MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells. FEBS Lett. 2013, 587:2247-2253.
39. Hollstein D., et al. p53 mutations in human cancers. Science 1991, 253:49-53.
40. Feki I., Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol. 2004, 52:103-116.
41. Oda E., et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058.
42. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene is induced by p53. Mol. Cell 2001, 7:683-694.
43. Fortin A., et al. APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death. J. Cell Biol. 2001, 155:207-216.
44. Moroni M.C., et al. Apaf-1 is a transcriptional target for E2F and p53. Nat. Cell Biol. 2001, 3:552-558.
45. Rampino N., et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275:967-969.
46. Mihara M., et al. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 2003, 11:577-590.
47. Chipuk J.E., et al. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2004, 309:1732-1735.
48. Nieminen A., et al. Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E1839-E1848.
49. Stahl M., et al. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J. Immunol. 2002, 168:5024-5031.
50. Dijkers P.F., et al. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. 2000, 10:1201-1204.
51. Sunters A., et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J. Biol. Chem. 2003, 278:49795-49805.
52. Yano T., et al. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis. Mol. Cell. Biol. 2006, 26:4474-4488.
53. Jin H.O., et al. Up-regulation of Bak and Bim via JNK downstream pathway in the response to nitric oxide in human glioblastoma cells. J. Cell. Physiol. 2006, 206:477-486.
54. Gogada R., et al. Bim, a proapoptotic protein, up-regulated via transcription factor E2F1-dependent mechanism, functions as a prosurvival molecule in cancer. J. Biol. Chem. 2013, 288:368-381.
55. Gilley J., et al. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J. Cell Biol. 2003, 162:613-622.
56. Costa D.B., et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007, 4:1669-1679.
57. Cragg M.S., et al. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 2007, 4:1681-1689.
58. Gong Y., et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 2007, 4:e294.
59. Faber A.C., et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 2011, 1:352-365.
60. Ng K.P., et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 2012, 18:521-528.
61. Melino G., et al. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J. Biol. Chem. 2004, 279:8076-8083.
62. You H., et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J. Exp. Med. 2006, 203:1657-1663.
63. Liedtke C., et al. The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism. J. Biol. Chem. 2003, 278:27593-27604.
64. Nahle Z., et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat. Cell Biol. 2003, 4:859-864.
65. Baptiste-Okoh N., et al. Caspase 2 is both required for p53-mediated apoptosis and downregulated by p53 in a p21-dependent manner. Cell Cycle 2008, 7:1133-1138.
66. Furukawa Y., et al. Apaf-1 is a mediator of E2F-1-induced apoptosis. J. Biol. Chem. 2002, 277:39760-39768.
67. Coldwell M.J., et al. Initiation of Apaf-1 translation by internal ribosome entry. Oncogene 2000, 19:899-905.
68. Soengas M.S., et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207-211.
69. Dai D.L., et al. Reduced Apaf-1 expression in human cutaneous melanomas. Br. J. Cancer 2004, 91:1089-1095.
70. Fujimoto A., et al. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res. 2004, 64:2245-2250.
71. Umetani N., et al. Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colorectal carcinoma. Oncogene 2004, 23:8292-8300.
72. Zlobec I., et al. Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. Eur. J. Cancer 2007, 43:1101-1107.
73. Wang H.L., et al. Rationales for expression and altered expression of apoptotic protease activating factor-1 gene in gastric cancer. World J. Gastroenterol. 2007, 13:5060-5064.
74. Christoph F., et al. A gene expression profile of tumor suppressor genes commonly methylated in bladder cancer. J. Cancer Res. Clin. Oncol. 2007, 133:343-349.
75. Hinz S., et al. EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder. Tumour Biol. 2007, 28:151-157.
76. Vucic D., et al. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat. Rev. Mol. Cell Biol. 2011, 12:439-452.
77. Dai C., Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol. Med. 2010, 16:528-536.
78. Kurokawa M., Kornbluth S. Caspases and kinases in a death grip. Cell 2009, 138:838-854.
79. Weissman A.M., et al. The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat. Rev. Mol. Cell Biol. 2011, 12:605-620.
80. Kurokawa M., et al. A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. Sci. Signal. 2013, 6:ra32.
81. Maurer U., et al. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 2005, 21:749-760.
82. Magiera M.M., et al. Trim17-mediated ubiquitination and degradation of Mcl-1 initiate apoptosis in neurons. Cell Death Differ. 2013, 20:281-292.
83. Stewart D.P., et al. Ubiquitin-independent degradation of antiapoptotic MCL-1. Mol. Cell. Biol. 2010, 30:3099-3110.
84. Ding Q., et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell. Biol. 2007, 27:4006-4017.
85. Morel C., et al. Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Mol. Cell. Biol. 2009, 29:3845-3852.
86. Liao M., et al. Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cells. Mol. Cancer 2011, 10:44.
87. Nifoussi S.K., et al. Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer. PLoS ONE 2012, 7:e47060.
88. Ding Q., et al. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res. 2007, 67:4564-4571.
89. Harley M.E., et al. Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J. 2010, 29:2407-2420.
90. Inuzuka H., et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011, 471:104-109.
91. Wertz I.E., et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011, 471:110-114.
92. Akhoondi S., et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007, 67:9006-9012.
93. Maser R.S., et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007, 47:966-971.
94. Wood L.D., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
95. Zhong Q., et al. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005, 121:1085-1095.
96. Pervin S., et al. Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells. Br. J. Cancer 2011, 105:428-437.
97. Schwickart M., et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010, 463:103-107.
98. Ley R., et al. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J. Biol. Chem. 2003, 278:18811-18816.
99. Luciano F., et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003, 22:6785-6793.
100. Akiyama T., et al. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J. 2003, 22:6653-6664.
101. Dehan E., et al. betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol. Cell 2009, 33:109-116.
102. Thompson S., et al. Identification of a novel Bcl-2-interacting mediator of cell death (Bim) E3 ligase, tripartite motif-containing protein 2 (TRIM2), and its role in rapid ischemic tolerance-induced neuroprotection. J. Biol. Chem. 2011, 286:19331-19339.
103. Zhang W., et al. RACK1 and CIS mediate the degradation of BimEL in cancer cells. J. Biol. Chem. 2008, 283:16416-16426.
104. Walter K.G., et al. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol. 1998, 139:1281-1292.
105. Schellenberg B., et al. Bax exists in a dynamic equilibrium between the cytosol and mitochondria to control apoptotic priming. Mol. Cell 2013, 49:959-971.
106. Edlich F., et al. Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell 2011, 145:104-116.
107. Liu F.T., et al. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 2008, 111:2797-2805.
108. Benard G., et al. IBRDC2, an IBR-type E3 ubiquitin ligase, is a regulatory factor for Bax and apoptosis activation. EMBO J. 2010, 29:1458-1471.
109. Agrawal S.G., et al. Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. Blood 2008, 111:2790-2796.
110. Fu N.Y., et al. Baxβ: a constitutively active human Bax isoform that is under tight regulatory control by the proteasomal degradation mechanism. Mol. Cell 2009, 33:15-29.
111. Zha J., et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996, 87:619-628.
112. Datta S.R., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
113. del Peso L., et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278:687-689.
114. Putcha G.V., et al. JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron 2003, 38:899-914.
115. Becker E.B., et al. Characterization of the c-Jun N-terminal kinase-BimEL signaling pathway in neuronal apoptosis. J. Neurosci. 2004, 24:8762-8770.
116. Harada H., et al. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:15313-15317.
117. Cai B., et al. p38 MAP kinase mediates apoptosis through phosphorylation of BimEL at Ser-65. J. Biol. Chem. 2006, 281:25215-25222.
118. Kim J., et al. Rsk-mediated phosphorylation and 14-3-3e{open} binding of Apaf-1 suppresses cytochrome c-induced apoptosis. EMBO J. 2012, 31:1279-1292.
119. Clark D.E., et al. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res. 2005, 65:3108-3116.
120. Kurokawa M., et al. Inhibition of apoptosome formation by suppression of Hsp90β phosphorylation in tyrosine kinase-induced leukemias. Mol. Cell. Biol. 2007, 28:5494-5506.
121. Desagher S., et al. Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Mol. Cell 2001, 8:601-611.
122. Shin S., et al. Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. EMBO J. 2005, 24:3532-3542.
123. Nutt K.L., et al. Metabolic regulation of oocyte cell death through the CaMKII-mediated phosphorylation of caspase-2. Cell 2005, 123:89-103.
124. Andersen J.L., et al. Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2. EMBO J. 2009, 28:3216-3227.
125. Voss O.H., et al. Regulation of monocyte apoptosis by the protein kinase Cdelta-dependent phosphorylation of caspase-3. J. Biol. Chem. 2005, 280:17371-17379.
126. Alvarado-Kristensson M., et al. p38-MAPK signals survival by phosphorylation of caspase-8 and caspase-3 in human neutrophils. J. Exp. Med. 2004, 199:449-458.
127. Li X., et al. Phosphorylation of caspase-7 by p21-activated protein kinase (PAK) 2 inhibits chemotherapeutic drug-induced apoptosis of breast cancer cell lines. J. Biol. Chem. 2011, 286:22291-22299.
128. Jia S.H., et al. Dynamic regulation of neutrophil survival through tyrosine phosphorylation or dephosphorylation of caspase-8. J. Biol. Chem. 2008, 283:5402-5413.
129. Cursi S., et al. Src kinase phosphorylates caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J. 2006, 25:1895-1905.
130. Martin M.C., et al. Protein kinase A regulates caspase-9 activation by Apaf-1 downstream of cytochrome c. J. Biol. Chem. 2005, 280:15449-15455.
131. Allan L.A., et al. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat. Cell Biol. 2003, 5:647-654.
132. Dessauge F., et al. Identification of PP1alpha as a caspase-9 regulator in IL-2 deprivation-induced apoptosis. J. Immunol. 2006, 177:2441-2451.
133. Allan A.L., Clarke P.R. Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol. Cell 2007, 26:301-310.
134. Laguna A., et al. The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development. Dev. Cell 2008, 15:841-853.
135. Seifert A., et al. DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine. FEBS J. 2008, 275:6268-6280.
136. Seifert A., Clarke P.R. p38alpha- and DYRK1A-dependent phosphorylation of caspase-9 at an inhibitory site in response to hyperosmotic stress. Cell. Signal. 2009, 21:1626-1633.
137. Brady S.C., et al. Regulation of caspase 9 through phosphorylation by protein kinase C zeta in response to hyperosmotic stress. Mol. Cell. Biol. 2005, 25:10543-10555.
138. Raina D., et al. c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic response to DNA damage. J. Biol. Chem. 2005, 280:11147-11151.
139. Cardone M.H., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1321.
140. Zinkel S.S., et al. A role for proapoptotic BID in the DNA-damage response. Cell 2005, 122:579-591.
141. Chakraborty A.R., et al. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood 2013, 121:4115-4125.
142. Leung K.T., et al. Activation of the JNK pathway promotes phosphorylation and degradation of BimEL--a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia. Carcinogenesis 2008, 29:544-551.
143. Moujalled D., et al. Cyclic-AMP-dependent protein kinase A regulates apoptosis by stabilizing the BH3-only protein Bim. EMBO Rep. 2011, 12:77-83.
144. Fricker M., et al. Phosphorylation of Puma modulates its apoptotic function by regulating protein stability. Cell Death Dis. 2010, 1:e59.
145. Sandow J.J., et al. Cytokine receptor signaling activates an IKK-dependent phosphorylation of PUMA to prevent cell death. Cell Death Differ. 2012, 19:633-641.
146. Yan J., et al. Inactivation of BAD by IKK inhibits TNFα-induced apoptosis independently of NF-κB activation. Cell 2013, 152:304-315.
147. Ye D.Z., et al. p21-Activated kinase 1 (Pak1) phosphorylates BAD directly at serine 111 in vitro and indirectly through Raf-1 at serine 112. PLoS ONE 2011, 6:e27637.
148. Harada H., et al. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol. Cell 1999, 3:413-422.
149. Bonni A., et al. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999, 286:1358-1362.
150. Fang X., et al. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 1999, 18:6635-6640.
151. Tan Y., et al. p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. J. Biol. Chem. 1999, 274:34859-34867.
152. Schürmann A., et al. p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol. Cell. Biol. 2000, 20:453-461.
153. Gnesutta N., et al. The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis. J. Biol. Chem. 2001, 276:14414-14419.
154. Cotteret S., et al. p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol. Cell. Biol. 2003, 23:5526-5539.
155. Jin Z., et al. Survival function of protein kinase Cι as a novel nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-activated bad kinase. J. Biol. Chem. 2005, 280:16045-16052.
156. Harada H., et al. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:9666-9670.
157. Tan Y., et al. BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J. Biol. Chem. 2000, 275:25865-25869.
158. Lizcano J.M., et al. Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochem. J. 2000, 349:547-557.
159. Lowman X.H., et al. The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. Mol. Cell 2010, 40:823-833.
160. Lei K., Davis R.J. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2432-2437.
161. Shao Y., Aplin A.E. ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity. Cell Death Dis. 2012, 3:e253.
162. Lopez J., et al. Src tyrosine kinase inhibits apoptosis through the Erk1/2- dependent degradation of the death accelerator Bik. Cell Death Dis. 2012, 19:1459-1469.
163. Arokium H., et al. Substitutions of potentially phosphorylatable serine residues of Bax reveal how they may regulate its interaction with mitochondria. J. Biol. Chem. 2007, 282:35104-35112.
164. Linseman D.A., et al. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J. Neurosci. 2004, 24:9993-10002.
165. Shen Z.J., et al. The peptidyl-prolyl isomerase Pin1 facilitates cytokine-induced survival of eosinophils by suppressing Bax activation. Nat. Immunol. 2009, 10:257-265.
166. Gardai S.J., et al. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J. Biol. Chem. 2004, 279:21085-21095.
167. Xin M., Deng X. Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation. J. Biol. Chem. 2006, 281:18859-18867.
168. Xin M., et al. Protein kinase Cζ abrogates the proapoptotic function of Bax through phosphorylation. J. Biol. Chem. 2007, 282:21268-21277.
169. Kim B.J., et al. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J. Biol. Chem. 2006, 281:21256-21265.
170. Owens T.W., et al. Apoptosis commitment and activation of mitochondrial Bax during anoikis is regulated by p38MAPK. Cell Death Differ. 2009, 16:1551-1562.
171. Fox J.L., et al. Tyrosine dephosphorylation is required for Bak activation in apoptosis. EMBO J. 2010, 29:3852-3868.
172. Azad A., et al. Blockade of the BAK hydrophobic groove by inhibitory phosphorylation regulates commitment to apoptosis. PLoS ONE 2012, 7:e49601.
173. Wang J., et al. Bcl-xL phosphorylation at Ser49 by polo kinase 3 during cell cycle progression and checkpoints. Cell. Signal. 2011, 23:2030-2038.
174. Terrano D., et al. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol. Cell. Biol. 2010, 30:640-656.
175. Wang J., et al. Phospho-Bcl-x(L)(Ser62) plays a key role at DNA damage-induced G(2) checkpoint. Cell Cycle 2012, 11:2159-2169.
176. Ito T., et al. Bcl-2 phosphorylation required for anti-apoptosis function. J. Biol. Chem. 1997, 272:11671-11673.
177. Deng X., et al. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:1578-1583.
178. Yamamoto K., et al. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol. Cell. Biol. 1999, 19:8469-8478.
179. Dimmeler S., et al. Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. J. Exp. Med. 1999, 189:1815-1822.
180. Breitschopf K., et al. Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol. Cell. Biol. 2000, 20:1886-1896.
181. Kobayashi S., et al. Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J. Biol. Chem. 2007, 282:18407-18417.
182. Johnson C.E., et al. Differential Apaf-1 levels allow cytochrome c to induce apoptosis in brain tumors but not in normal neural tissues. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:20820-20825.
183. Tamm I., et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol. J. 2004, 5:489-495.
184. Burstein D.E., et al. Immunohistochemical detection of the X-linked inhibitor of apoptosis protein (XIAP) in cervical squamous intraepithelial neoplasia and squamous carcinoma. Ann. Diagn. Pathol. 2008, 12:85-89.
185. Moussata D., et al. XIAP as a radioresistance factor and prognostic marker for radiotherapy in human rectal adenocarcinoma. Am. J. Pathol. 2012, 181:1271-1278.
186. Dan H.C., et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. 2004, 279:5405-5412.
187. Nakhaei P., et al. IκB kinase e{open}-dependent phosphorylation and degradation of X-linked inhibitor of apoptosis sensitizes cells to virus-induced apoptosis. J. Virol. 2012, 86:726-737.
188. Oltersdorf T., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2012, 435:677-681.
189. Tse C., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68:3421-3428.
190. Souers A.J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19:202-208.
191. Yecies D., et al. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010, 115:3304-3313.
192. Wei G., et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 2012, 21:547-562.
193. Cohen N.A., et al. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem. Biol. 2012, 19:1175-1186.
194. Vo T.T., et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012, 151:344-355.
195. Parrish A.B., et al. Cellular mechanisms controlling caspase activation and function. Cold Spring Harb. Perspect. Biol. 2013, 5:a008672.
196. Tait S.W., et al. Resistance to caspase-independent cell death requires persistence of intact mitochondria. Dev. Cell 2010, 18:802-813.
197. Suzuki A., et al. Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene 2004, 23:7067-7075.
198. Peng C., et al. Phosphorylation of caspase-8 (Thr-263) by ribosomal S6 kinase 2 (RSK2) mediates caspase-8 ubiquitination and stability. J. Biol. Chem. 2011, 286:6946-6954.
199. Matthess Y., et al. Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. Mol. Cell. Biol. 2010, 30:5726-5740.